Stereotaxis (STXS) 10-K 9 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Feb. 28, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-36159
Entity Registrant Name	STEREOTAXIS, INC.
Entity Central Index Key	0001289340
Entity Tax Identification Number	94-3120386
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	710 North Tucker Boulevard
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	St. Louis
Entity Address, State or Province	MO
Entity Address, Postal Zip Code	63101
City Area Code	(314)
Local Phone Number	678-6100
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	STXS
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 110.7
Entity Common Stock, Shares Outstanding		75,045,484
Documents incorporated by reference	Portions of the Proxy Statement for the registrant’s 2023 Annual Meeting of Shareholders are incorporated by reference in Part III, Items 10, 11, 12, 13 and 14.
ICFR Auditor Attestation Flag	false
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	St. Louis, Missouri

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 8,586	$ 38,739
Restricted cash - current	525	453
Short-term investments	19,844
Accounts receivable, net of allowance of $235 and $180 at 2022 and 2021, respectively	5,090	5,406
Inventories, net	7,876	4,433
Prepaid expenses and other current assets	1,325	2,356
Total current assets	43,246	51,387
Property and equipment, net	3,831	2,632
Restricted cash	744	952
Operating lease right-of-use assets	5,384	5,736
Prepaid and other non-current assets	208	278
Total assets	53,413	60,985
Current liabilities:
Accounts payable	3,270	4,189
Accrued liabilities	3,306	2,528
Deferred revenue	7,342	6,277
Current portion of operating lease liabilities	373	268
Total current liabilities	14,291	13,262
Long-term deferred revenue	1,654	2,238
Operating lease liabilities	5,488	5,842
Other liabilities	51	218
Total liabilities	21,484	21,560
Series A - Convertible preferred stock:
Convertible preferred stock, Series A, par value $0.001; 22,383 and 22,387 shares outstanding at 2022 and 2021, respectively	5,583	5,584
Stockholders’ equity:
Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2022 and 2021	6	6
Common stock, par value $0.001; 300,000,000 shares authorized, 74,874,459 and 74,618,240 shares issued at 2022 and 2021, respectively	75	75
Additional paid in capital	543,438	532,641
Treasury stock, 4,015 shares at 2022 and 2021	(206)	(206)
Accumulated deficit	(516,967)	(498,675)
Total stockholders’ equity	26,346	33,841
Total liabilities and stockholders’ equity	$ 53,413	$ 60,985

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 235	$ 180
Series A convertible preferred stock, par value	$ 0.001	$ 0.001
Series A convertible preferred stock, shares outstanding	22,383	22,387
Series B convertible preferred stock, par value	$ 0.001	$ 0.001
Series B convertible preferred stock, shares authorized	10,000,000	10,000,000
Series B convertible preferred stock, shares outstanding	5,610,121	5,610,121
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	74,874,459	74,618,240
Treasury stock, shares	4,015	4,015

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 28,147	$ 35,021
Cost of revenue:
Total cost of revenue	9,677	11,789
Gross margin	18,470	23,232
Operating expenses:
Research and development	10,558	10,199
Sales and marketing	12,325	11,948
General and administrative	14,363	13,973
Total operating expenses	37,246	36,120
Operating loss	(18,776)	(12,888)
Interest income (expense), net	484	(11)
Gain on extinguishment of debt		2,183
Net loss	(18,292)	(10,716)
Cumulative dividend on convertible preferred stock	(1,343)	(1,345)
Net loss attributable to common stockholders	$ (19,635)	$ (12,061)
Net loss per share attributable to common stockholders:
Basic	$ (0.26)	$ (0.16)
Diluted	$ (0.26)	$ (0.16)
Weighted average number of common shares and equivalents:
Basic	76,061,183	75,558,233
Diluted	76,061,183	75,558,233
Systems [Member]
Revenue:
Total revenue	$ 6,845	$ 11,168
Cost of revenue:
Total cost of revenue	5,802	7,527
Disposables Service And Accessories [Member]
Revenue:
Total revenue	21,302	22,867
Cost of revenue:
Total cost of revenue	3,875	3,276
Sublease [Member]
Revenue:
Total revenue		986
Cost of revenue:
Total cost of revenue		$ 986

Statements of Convertible Prefe

Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($) $ in Thousands	Convertible preferred stock series A [Member]	Convertible preferred stock series B [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 5,605	$ 6	$ 74	$ 522,710	$ (206)	$ (487,959)	$ 34,625
Beginning balance, shares at Dec. 31, 2020	22,513	5,610,121	73,694,203
Stock issued for the exercise of stock options and stock appreciation rights			$ 1	429			430
Issuance of common stock, shares			332,232
Stock-based compensation				9,363			9,363
Share-based compensation, shares			325,954
Components of net loss						(10,716)	(10,716)
Employee stock purchase plan				118			118
Employee stock purchase plan, shares			19,699
Preferred stock conversion	$ (21)			21			21
Preferred stock conversion, shares	(126)		246,152
Ending balance, value at Dec. 31, 2021	$ 5,584	$ 6	$ 75	532,641	(206)	(498,675)	33,841
Ending balance, shares at Dec. 31, 2021	22,387	5,610,121	74,618,240
Stock issued for the exercise of stock options and stock appreciation rights				102			$ 102
Issuance of common stock, shares			92,377				131,375
Stock-based compensation				10,576			$ 10,576
Share-based compensation, shares			110,726
Components of net loss						(18,292)	(18,292)
Employee stock purchase plan				118			118
Employee stock purchase plan, shares			44,783
Preferred stock conversion	$ (1)			1			1
Preferred stock conversion, shares	(4)		8,333
Ending balance, value at Dec. 31, 2022	$ 5,583	$ 6	$ 75	$ 543,438	$ (206)	$ (516,967)	$ 26,346
Ending balance, shares at Dec. 31, 2022	22,383	5,610,121	74,874,459

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (18,292)	$ (10,716)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	429	106
Non-cash lease expense	103	324
Stock-based compensation	10,576	9,363
Gain on debt extinguishment		(2,183)
Non-cash interest		25
Accretion of short-term investment discount	(128)
Changes in operating assets and liabilities:
Accounts receivable	316	(1,891)
Inventories	(2,906)	(1,138)
Prepaid expenses and other current assets	1,031	(640)
Compensating cash arrangement		251
Other assets	70	30
Accounts payable	(169)	1,434
Accrued liabilities	(267)	(681)
Deferred revenue	989	2,683
Other liabilities	(167)	87
Net cash used in operating activities	(8,415)	(2,946)
Cash flows from investing activities
Purchase of property and equipment	(2,378)	(1,397)
Purchases of short-term investments	(19,716)
Net cash used in investing activities	(22,094)	(1,397)
Cash flows from financing activities
Proceeds from issuance of stock, net of issuance costs	220	547
Net cash provided by financing activities	220	547
Net decrease in cash, cash equivalents, and restricted cash	(30,289)	(3,796)
Cash, cash equivalents, and restricted cash at beginning of period	40,144	43,940
Cash, cash equivalents, and restricted cash at end of period	9,855	40,144
Supplemental disclosure of cash flow information:
Interest paid
Purchase of property and equipment included in accounts payable	313	1,146
Reconciliation of cash, cash equivalents, and restricted cash to balance sheet as of December 31st:
Cash and cash equivalents	8,586	38,739
Restricted cash - current	525	453
Restricted cash	744	952
Total cash, cash equivalents, and restricted cash	$ 9,855	$ 40,144

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. Description of Business Stereotaxis designs, manufactures and markets robotic systems, instruments and information systems for the interventional laboratory. Our proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Direct control of the tip of an interventional device, in contrast to all manual hand-held devices that are controlled from their handle, can improve the precision, stability, reach and safety of these devices during procedures. Our primary clinical focus has been electrophysiology, specifically cardiac ablation procedures for the treatment of arrhythmias. Cardiac ablation has become a well-accepted therapy for arrhythmias and a multi-billion-dollar medical device market with expectations for substantial long-term growth. We have shared our aspiration and a product strategy to expand the clinical focus of our technology to several additional endovascular indications including coronary, neuro, and peripheral interventions. There is substantial real-world evidence and clinical literature for Robotic Magnetic Navigation in electrophysiology. Hundreds of electrophysiologists at over one hundred hospitals globally have treated over 100,000 arrhythmia patients with our robotic technology. Clinical use of our technology has been documented in over 400 clinical publications. Robotic Magnetic Navigation is designed to enable physicians to complete more complex interventional procedures with greater success and safety by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied computer-controlled magnetic fields that govern the motion of the working tip of the catheter, resulting in improved navigation. The more flexible atraumatic design of catheters driven using magnetic fields may reduce the risk of patient harm and other adverse events. Performing the procedure from a control cockpit enables physicians to complete procedures in a safe location protected from x-ray exposure, with greater ergonomics, and improved efficiency. We believe these benefits can be applicable in other endovascular indications where navigation through complex vasculature is often challenging or unsuccessful and generates significant x-ray exposure. Our primary products include the Genesis RMN Odyssey The Genesis RMN System The Odyssey Solution Odyssey Cinema, The Stereotaxis Imaging Model S provides an integrated complete solution for a robotic interventional operating room. It is a single-plane, full-power x-ray system and includes the c-arm, powered table, motorized boom, and large high-definition monitors. Stereotaxis Imaging Model S incorporates modern fluoroscopy technology to support high quality imaging while minimizing radiation exposure for patients and physicians. The combination of RMN Systems with Stereotaxis Imaging Model S is designed to reduce the cost of acquisition, the ongoing cost of ownership, and the complexity of installation of a robotic electrophysiology practice. We promote our full suite of products in a typical hospital implementation, subject to regulatory approvals or clearances. This implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and ongoing software updates. In hospitals where our full suite of products has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. We have received regulatory clearances and registration necessary for us to market the Genesis RMN Niobe Odyssey Cardiodrive Vdrive Vdrive Duo V-CAS V-Loop V-Sono We have strategic relationships with technology leaders and innovators in the global interventional market. Through these strategic relationships we provide compatibility between our robotic magnetic navigation system and digital imaging and 3D catheter location sensing technology, as well as disposable interventional devices. The maintenance of these strategic relationships, or the establishment of equivalent alternatives, is critical to our commercialization efforts. There are no guarantees that any existing strategic relationships will continue, and efforts are ongoing to ensure the availability of integrated systems and devices and/or equivalent alternatives. We cannot provide assurance as to the timeline of the ongoing availability of such compatible systems or our ability to obtain equivalent alternatives on competitive terms or at all.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Cash and Cash Equivalents Cash and cash equivalents include cash on hand, money market instruments, and other highly liquid investments with original maturities of three months or less from the date of purchase. Restricted Cash Restricted cash primarily consists of cash that the Company is obligated to maintain in accordance with contractual obligations. Investments Our investments may include, at any time, a diversified portfolio of cash equivalents and short- and long-term investments in a variety of high-quality securities, including money market funds, U.S. treasury and U.S. government agency securities, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and municipal notes. As of December 31, 2022, the Company’s short-term investments consisted of U.S. treasury securities and fixed maturity, marketable debt securities with original maturities at the time of purchase of one year or less, but greater than 90 days. These investments are classified as held to maturity. Securities classified as held to maturity are securities that the Company has the ability and intent to hold to maturity or redemption and are carried at amortized cost. Amortized cost of U.S. treasury securities and marketable debt securities are based on the Company’s purchase price adjusted for accrual of discount, or amortization of premium, and recognition of impairment charges, if any. The amortized cost of securities the Company purchases at a discount or premium will equal the face or par value at maturity or the call date, if applicable. Interest is reported as income when earned and is adjusted for amortization or accretion of any premium or discount. There were no impairments for the year ended December 31, 2022. Fair Value Measurements Financial instruments consist of cash and cash equivalents, restricted cash, investments, accounts receivable, and accounts payable. The Company measures certain financial assets and liabilities at fair value on a recurring basis. General accounting principles for fair value measurement establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below: Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market. Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market. As of December 31, 2022, financial assets that are classified as Level 2 include money market funds, U.S. treasury securities and corporate debt securities. As of December 31, 2021, financial assets that are classified as Level 2 include money market funds. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy. Compensating Cash Arrangement In July 2020, the Company entered into a letter of credit to support a commitment of less than $ 0.3 0.3 Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators. Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or net realizable value. The Company periodically reviews its physical inventory and provides a reserve upon identification of potential excess or obsolete items. Excess manufacturing overhead costs attributable to idle facility expenses or abnormally low production volumes are excluded from inventory and recorded as an expense in the period incurred. Property and Equipment Property and equipment consist primarily of leasehold improvements, construction in process, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years. Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 3 inputs. Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10 15 Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates. Revenue and Costs of Revenue Revenue Recognition The Company accounts for revenue in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), Revenue from Contracts with Customers We generate revenue from initial capital sales of systems as well as recurring revenue from the sale of our proprietary disposable devices, from royalties paid to the Company on the sale of various devices as provided by co-development and co-placement arrangements, and from revenue including ongoing software updates and service contracts. We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We record our revenue based on consideration specified in the contract with each customer, net of any taxes collected from customers that are remitted to government authorities. For contracts containing multiple products and services the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer. For arrangements with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services and market conditions. The Company regularly reviews standalone selling prices and updates these estimates if necessary. Our revenue recognition policy affects the following revenue streams in our business as follows: Systems: Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation and an implied obligation to provide software enhancements if and when available for one year following installation. Revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. Revenue from the implied obligation to deliver software enhancements if and when available is recognized ratably over the first year following installation of the system as the customer receives the right to software updates throughout the period and is included in Other Recurring Revenue. The Company’s system contracts generally do not provide a right of return. Systems are generally covered by a one-year assurance type warranty; warranty costs were approximately $ 0.1 0.2 24 32 Disposables: Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but can also occur at the time of delivery depending on the customer arrangement. Disposable products are covered by an assurance type warranty that provides for the return of defective products. Warranty costs were not material for the periods presented. Disposable revenue represented 28 24 Royalty: The Company received royalty payments from Biosense Webster, payable quarterly based on net revenues from sales of the co-developed catheters. Royalty revenue from the co-developed catheters represented 7 % of revenue for the years ended December 31, 2022 and 2021. Other Recurring Revenue: Other recurring revenue includes revenue from product maintenance plans, other post warranty maintenance, and the implied obligation to provide software enhancements if and when available for a specified period, typically one year following installation of our systems. Revenue from services and software enhancements is deferred and amortized over the service or update period, which is typically one year. Revenue related to services performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 41 34 Sublease Revenue: A portion of our principal executive office was subleased to a third party through 2021. In accordance with Accounting Standards Update (ASU) 2016-02, “Leases” (Topic 842), the Company recorded sublease income as revenue. Sublease revenue represented 3 The following table summarizes the Company’s revenue for systems, disposables, service and accessories and sublease for the years ended December 31, 2022 and 2021 (in thousands): Schedule of Revenue Disaggregated by Type 2022 2021 Year Ended December 31, 2022 2021 Systems $ 6,845 $ 11,168 Disposables, service and accessories 21,302 22,867 Sublease - 986 Total revenue $ 28,147 $ 35,021 Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to the Company’s systems contracts and obligations that will be recognized as revenue in future periods. These obligations are generally satisfied within two years after contract inception but may occasionally extend longer. Transaction price representing revenue to be earned on remaining performance obligations on system contracts was approximately $ 14.8 The following information summarizes the Company’s contract assets and liabilities (in thousands): Summary of Contract Assets and Liabilities December 31, 2022 December 31, 2021 Contract Assets - unbilled receivables $ 539 $ 178 Customer deposits $ 2,339 $ 925 Product shipped, revenue deferred 1,389 1,794 Deferred service and license fees 5,268 5,796 Total deferred revenue $ 8,996 $ 8,515 Less: Long-term deferred revenue (1,654 ) (2,238 ) Total current deferred revenue $ 7,342 $ 6,277 The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets primarily represent the difference between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Customer deposits primarily relate to future system sales but can also include deposits on disposable sales. Deferred revenue is primarily related to service contracts, for which the service fees are billed up-front, generally quarterly or annually, and for amounts billed in advance for system contracts for which some performance obligations remain outstanding. For service contracts, the associated deferred revenue is generally recognized ratably over the service period. For system contracts, the associated deferred revenue is recognized when the remaining performance obligations are satisfied. The Company did not have any impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended December 31, 2022 and 2021, that was included in the deferred revenue balance at the beginning of each reporting period was $ 5.9 5.1 The Company has determined that sales incentive programs for the Company’s sales team meet the requirements to be capitalized as the Company expects to generate future economic benefits from the related revenue generating contracts after the initial capital sales transaction. The costs capitalized as contract acquisition costs included in prepaid expenses and other assets in the Company’s balance sheets were $ 0.2 Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred. Leasing Arrangements A lease is defined as a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. The Company accounts for leases in accordance with Accounting Standards Update No. 2016-02 “Leases” (Topic 842) and all subsequent ASUs that modified Topic 842 (“ASC 842”). The Company determines if an arrangement contains a lease at inception. The Company leases its facilities under operating leases. In accordance with ASC 842, operating lease agreements are recognized on the balance sheet as a right-of-use (“ROU”) asset and a corresponding lease liability. These leases generally do not have significant rent escalation holidays, concessions, leasehold improvement incentives, or other build-out clauses. Further, the leases do not contain contingent rent provisions. Many of our leases include both lease (i.e., fixed payments including rent, taxes, and insurance costs) and non-lease components (i.e., common-area or other maintenance costs) which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. A portion of our prior principal executive office was subleased to a third party through 2021. The sublease did not have significant rent escalation holidays, concessions, leasehold improvement incentives, or other build-out clauses. In addition, the sublease did not contain contingent rent provisions nor were there options to extend or terminate the sublease. The sublease ended December 31, 2021. The Company’s lease agreements often include one or more options to renew at the Company’s discretion. If at lease inception, the Company considers the exercising of a renewal option to be reasonably certain, the Company will include the extended term in the calculation of the ROU asset and lease liability. The Company elected not to include short-term leases (i.e., leases with initial terms of twelve months or less) on the balance sheet. The calculated amounts of the ROU assets and lease liabilities are impacted by the length of the lease term and the discount rate used to calculate the present value of the minimum lease payments. ASC 842 requires the use of the discount rate implicit in the lease whenever this rate is readily determinable. As this rate is rarely determinable, the Company utilizes its incremental borrowing rate at lease inception. Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic relationships under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables as of December 31, 2022 or 2021 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned. Stock-Based Compensation The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the stock-based compensation at the grant date and the recognition of the related expense over the period in which the stock-based compensation vests. For time-based awards, the Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The weighted average assumptions and fair value for options granted during the year ended December 31, 2022, were 1) expected dividend rate of 0 80 6.25 For market-based awards, stock-based compensation expense is recognized over the minimum service period regardless of whether or not the market target is probable of being achieved. The fair value of such awards is estimated on the grant date using Monte Carlo simulations. Shares purchased by employees under the 2022 Employee Stock Purchase Plan are considered to be non-compensatory. Net Loss per Common Share Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our convertible preferred stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our convertible preferred stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our convertible preferred stock issued and outstanding during the period, except where the effect of such securities would be antidilutive. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2022, the Company had 3,208,065 4.21 47,364,216 5,610,121 1,208,739 Income Taxes In accordance with general accounting principles for income taxes , Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate. Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of government provided insurance on such deposits. No single customer accounted for more than 10% of total revenue for the years ended December 31, 2022 and 2021. Revenue from customers in China accounted for $ 3.7 10 Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments” and also issued subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04 and ASU 2019-05. The standard modifies the measurement approach for credit losses on financial instruments, including trade receivables, from an incurred loss method to a current expected credit loss method, otherwise known as “CECL.” The standard requires the measurement of expected credit losses to be based on relevant information, including historical experience, current conditions and a forecast that is supportable. The standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years; early adoption is permitted. The standard must be adopted by applying a cumulative adjustment to retained earnings. The Company anticipates adopting the standard in the first quarter of 2023, although it does not expect a significant impact to the Company’s financial results.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Financial Instruments	3. Financial Instruments The following table summarizes the Company’s cash and held to maturity securities’ amortized cost, gross unrealized gains, gross unrealized losses, and fair value by significant investment category reported as cash and cash equivalents, restricted cash and investments as of December 31, 2022, and 2021: Schedule of Cash and Held to Maturity Securities December 31, 2022 Valuation Balance Sheet Classification (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Restricted Cash- current Short-term Investments Restricted Cash Cash $ 3,258 $ - $ - $ 3,258 $ 3,258 $ - $ - $ - Level 2 Money market funds 1,615 - - 1,615 346 525 - 744 US treasury securities 14,833 2 (2 ) 14,833 4,982 - 9,851 - Corporate debt securities 9,993 - (6 ) 9,987 - - 9,993 - Subtotal 26,441 2 (8 ) 26,435 5,328 525 19,844 744 Total assets measured at fair value $ 29,699 $ 2 $ (8 ) $ 29,693 $ 8,586 $ 525 $ 19,844 $ 744 December 31, 2021 Valuation Balance Sheet Classification (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Restricted Cash- current Short-term Investments Restricted Cash Cash $ 38,739 $ - $ - $ 38,739 $ 38,739 $ - $ - $ - Level 2 Money market funds 1,405 - - 1,405 - 453 - 952 Subtotal 1,405 - - 1,405 - 453 - 952 Total assets measured at fair value $ 40,144 $ - $ - $ 40,144 $ 38,739 $ 453 $ - $ 952 Interest income recorded for these investments was $ 0.5 0.1 As of December 31, 2022, and 2021, the Company did not have any financial assets classified as Level 1 or Level 3 nor did the Company have financial liabilities valued at fair value on a recurring basis.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory	4. Inventory Inventory consists of the following (in thousands): Schedule of Inventories December 31, 2022 December 31, 2021 Raw materials $ 6,556 $ 3,642 Work in process 530 133 Finished goods 2,697 2,823 Reserve for excess and obsolescence (1,907 ) (2,165 ) Total inventory $ 7,876 $ 4,433

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other assets consist of the following (in thousands): Schedule of Prepaid Expenses and Other Assets December 31, 2022 December 31, 2021 Prepaid expenses $ 605 $ 1,012 Prepaid commissions 187 229 Deposits 669 1,276 Other assets 72 117 Total prepaid expenses and other assets 1,533 2,634 Less: Noncurrent prepaid expenses and other assets (208 ) (278 ) Total current prepaid expenses and other assets $ 1,325 $ 2,356

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	6. Property and Equipment Property and equipment consist of the following (in thousands): Schedule of Property and Equipment December 31, 2022 December 31, 2021 Equipment $ 4,393 $ 3,670 Leasehold improvements 2,692 17 Construction in process 204 2,156 Gross property and equipment 7,289 5,843 Less: Accumulated depreciation (3,458 ) (3,211 ) Net property and equipment $ 3,831 $ 2,632 The Company retired approximately $ 0.2 5.5 1.2 million and $ 2.5

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases
Leases	7. Leases On March 1, 2021, the Company entered into an office lease agreement (the “Lease”) with Globe Building Company (the “Landlord”), under which the Company leases executive office space and manufacturing facilities of approximately 43,100 ten years two five years 0.8 1.0 5.9 In the fourth quarter of 2021, the Company received an occupancy permit and relocated its operations to the new leased space. As of December 31, 2022, the weighted average discount rate for operating leases was 9% 8.99 The following table represents lease costs and other lease information (in thousands): Schedule of Lease Costs and Other Lease Information 2022 2021 Year Ended December 31, 2022 2021 Operating lease cost $ 909 $ 2,707 Short-term lease cost 28 57 Sublease income - (986 ) Total net lease cost $ 937 $ 1,778 Cash paid within operating cash flows $ 886 $ 2,223 Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our leased facilities and equipment which are paid based on actual costs incurred. Future minimum payments for operating leases with initial or remaining terms of one year or more as of December 31, 2022, were as follows (in thousands): Schedule of Future Minimum Operating Lease Payments December 31, 2022 2023 $ 877 2024 898 2025 919 2026 935 2027 956 2028 and thereafter 4,030 Total lease payments $ 8,615 Less: Interest (2,754 ) Present value of lease liabilities $ 5,861

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	8. Accrued Liabilities Accrued liabilities consist of the following (in thousands): Schedule of Accrued Liabilities December 31, 2022 December 31, 2021 Accrued salaries, bonus, and benefits $ 1,381 $ 1,516 Accrued licenses and maintenance fees 484 484 Accrued warranties 163 242 Accrued taxes 47 177 Accrued investigational sites 101 123 Accrued lease deposit payable - 124 Deferred contract obligation 1,045 - Other 136 80 Total accrued liabilities 3,357 2,746 Less: Long term accrued liabilities (51 ) (218 ) Total current accrued liabilities $ 3,306 $ 2,528

Debt and Credit Facilities

Debt and Credit Facilities	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt and Credit Facilities	9. Debt and Credit Facilities The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020 in the United States. Among the provisions contained in the CARES Act was the creation of the Paycheck Protection Program that provides for Small Business Administration (“SBA”) Section 7(a) loans for qualified small businesses. In general, the loan could be forgiven as long as the funds were used for payroll related expenses as well as rent and utilities paid during the twenty-four-week period from the date of the loan and as long as certain headcount and salary/wage levels were maintained. On April 10, 2020, the Company was informed by its lender, Midwest BankCentre (the “Bank”), that the Bank received approval from the SBA to fund the Company’s request for a loan under the SBA’s Paycheck Protection Program (“PPP Loan”). Per the terms of the PPP Loan, the Company received total proceeds of approximately $ 2.2 2.2

Convertible Preferred Stock and

Convertible Preferred Stock and Stockholders’ Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Convertible Preferred Stock and Stockholders’ Equity	10. Convertible Preferred Stock and Stockholders’ Equity The holders of common stock are entitled to one vote for each share held No Series B Convertible Preferred Stock On August 7, 2019, the Company entered into a Securities Purchase Agreement with certain institutional and other accredited investors, whereby it, as part of a private placement, agreed to issue and sell to the investors 5,610,121 0.001 2.05 Series A Convertible Preferred Stock and Warrants In September 2016, the Company issued (i) 24,000 0.001 1,000 0.65 36,923,078 6% 1,000 50% The SPA Warrants were modified on February 28, 2018 to allow for a reduction in the exercise price from $ 0.70 0.28 15,385 2021 CEO Performance Award Unit Grant On February 23, 2021, the Company`s Board of Directors, upon recommendation of the Compensation Committee, approved the grant of the CEO Performance Award to the Company’s Chief Executive Officer. The CEO Performance award is a 10 13,000,000 As detailed in the table below, the CEO Performance Award consists of ten vesting tranches. The first market capitalization milestone is $ 1.0 500 5.5 Summary of Performance Award And Market Capitalization Milestones Tranche # No. of Shares Subject to PSU Market Capitalization Milestones 1 1,000,000 $ 1,000,000,000 2 1,500,000 $ 1,500,000,000 3 1,500,000 $ 2,000,000,000 4 2,000,000 $ 2,500,000,000 5 1,000,000 $ 3,000,000,000 6 1,000,000 $ 3,500,000,000 7 1,000,000 $ 4,000,000,000 8 2,000,000 $ 4,500,000,000 9 1,000,000 $ 5,000,000,000 10 1,000,000 $ 5,500,000,000 Total: 13,000,000 Each tranche represents a portion of the PSUs covering the number of shares outlined in the table above. Each tranche vests upon (i) satisfaction of the market capitalization milestones and (ii) continued employment as CEO of the Company from the grant date through December 31, 2030. Absent an earlier termination, the PSUs will expire on December 31, 2030. If our CEO ceases employment as CEO of the Company for any reason including death, disability, termination for cause or without cause (as defined in the award agreement), or if he voluntary terminates after service as CEO for at least five years, the remaining service period will be waived and he will retain any PSUs that have vested through the date of termination The Company received Shareholder approval at its annual meeting on May 20, 2021 for shares to be issued under the award. The market capitalization requirement is considered a market condition under FASB Accounting Standards Codification Topic 718 “Compensation – Stock Compensation” and is estimated on the grant date using Monte Carlo simulations. Recognition of stock-based compensation expense of all the tranches commenced on February 23, 2021, the date of grant, as the probability of meeting the ten market capitalization milestones is not considered in determining the timing of expense recognition. The expense will be recognized on an accelerated basis through 2030. Key assumptions for estimating the performance-based awards fair value at the date of grant included share price on grant date, volatility of the Company’s common stock price, risk free interest rate, and grant term. Total stock-based compensation recorded as operating expense for the CEO Performance Award was $ 7.1 6.1 44.1 51.3 As of December 31, 2022, none of the performance milestones established by the 2021 CEO Incentive Program have been achieved and no awards have been earned. Stock Award Plans The Company has various stock plans that permit the Company to provide incentives to employees, directors, and third-party consultants of the Company in the form of equity compensation. In February 2022, the Compensation Committee of the Board of Directors adopted the 2022 Stock Incentive Plan (the “Plan”) which was subsequently approved by the Company’s shareholders. This plan replaced the 2012 Stock Incentive Plan which expired on May 19, 2022 As of December 31, 2022, the Company had 3,930,952 The 2022 Stock Incentive Plan allows for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted shares and restricted share units to employees, directors, and third-party consultants. Options granted under the 2022 Stock Incentive Plan expire no later than ten years 100% 25% three years 25% three years ten years Restricted stock unit grants are time-based and generally vest over a period of four years ten years The exercise price of options to non-employee directors shall not be less than 100% one five years As of December 31, 2022, the total compensation cost related to options, stock appreciation rights, and non-vested stock granted to employees and non-employees under the Company’s stock award plans but not yet recognized was approximately $ 4.7 four years A summary of the option and stock appreciation rights activity for the year ended December 31, 2022 is as follows: Summary of Option and Stock Appreciation Rights Activity Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share Outstanding, December 31, 2021 2,818,012 $ 0.74 9.87 $ 4.10 Granted 843,500 $ 2.09 5.21 $ 4.49 Exercised (131,375 ) $ 0.74 4.52 $ 1.48 Forfeited (322,072 ) $ 0.74 7.70 $ 5.09 Outstanding, December 31, 2022 3,208,065 $ 0.74 9.87 $ 4.21 As of December 31, 2022, the weighted average remaining contractual life of the options and stock appreciation rights outstanding was 7.40 3,208,065 1,749,297 3.42 6.45 A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows: Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price Year Ended December 31, 2022 Number of Weighted Weighted Weighted Options Average Exercise Options Average Average Currently Price Per Vested Range of Exercise Prices Outstanding Remaining Life Exercise Price Exercisable Share $ 0.00 1.00 345,364 5.16 $ 0.74 345,364 $ 0.74 $ 1.01 2.00 84,995 9.35 $ 1.59 7,995 $ 1.19 $ 2.01 4.00 631,339 5.99 $ 2.08 578,202 $ 2.07 $ 4.01 10.00 2,146,367 8.10 $ 5.50 817,736 $ 5.52 3,208,065 7.40 $ 4.21 1,749,297 $ 3.42 The intrinsic value of options and stock appreciation rights is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for the options and stock appreciation rights that were in-the-money as of December 31, 2022. The intrinsic value of the options and stock appreciation rights outstanding as of December 31, 2022 was approximately $ 0.5 2.07 881,207 0.1 The intrinsic value of the options and stock appreciation rights outstanding at December 31, 2021 was approximately $ 6.6 6.20 1,229,610 1.9 The weighted average grant date fair value of options granted during the years ended December 31, 2022 and 2021 was $ 4.49 7.10 A summary of the restricted stock unit activity for the year ended December 31, 2022 is as follows: Summary of Restricted Stock Unit Activity Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit Outstanding, December 31, 2021 1,164,723 $ 3.57 Granted 154,742 $ 7.68 Vested (110,726 ) $ 2.27 Outstanding, December 31, 2022 1,208,739 $ 4.21 The intrinsic value of restricted stock units outstanding as of December 31, 2022 was $ 2.5 2.07 The intrinsic value of restricted stock units outstanding at December 31, 2021 was $ 7.2 6.20 0.3 2022 Employee Stock Purchase Plan In 2022, the Company adopted its 2022 Employee Stock Purchase Plan (“ESPP”). Eligible employees have the opportunity to participate in a new purchase period every 3 months. Under the terms of the plan, employees can purchase up to 15% 25,000 95% 164,654 The Company has reserved shares of common stock for conversion of convertible preferred stock, and the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows: Summary of Reserved Shares of Common Stock for Conversion December 31, 2022 December 31, 2021 Series A Convertible Preferred Stock 45,023,612 45,031,944 Series B Convertible Preferred Stock 5,610,121 5,610,121 Performance Share Unit Plan 13,000,000 13,000,000 Stock award plans 3,930,952 4,909,848 Employee Stock Purchase Plan 164,654 209,437 Reserved shares of common stock 67,729,339 68,761,350

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes The provision for income taxes consists of the following (in thousands): Schedule of Provision For Income Taxes 2022 2021 Year Ended December 31, 2022 2021 Deferred: Federal $ (1,990 ) $ (1,723 ) State and local (93 ) 1 Total deferred income tax expense (benefit) (2,083 ) (1,722 ) Valuation allowance 2,083 1,722 Income tax benefit $ — $ — The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following: Schedule of Reconciliation of Federal Income Tax Rate 2022 2021 Year Ended December 31, 2022 2021 U.S. statutory income tax rate 21.0 % 21.0 % State and local taxes, net of federal tax benefit 1.1 % 1.4 % Stock compensation permanent differences between book and tax (7.1 )% (10.1 )% Other permanent differences between book and tax (3.0 )% 5.3 % State rate adjustments (0.6 )% (1.5 )% Valuation allowance (11.4 )% (16.1 )% Effective income tax rate — % — % The stock compensation permanent difference relates to the February 3, 2021 Board approved grant of Performance Share Unit Award pursuant to the CEO Performance Share Unit Award Agreement (the “PSU Agreement”) to David L. Fischel, the Company’s Chief Executive Officer. Total stock-based compensation attributed to the PSU Agreement was $ 7.1 6.1 The components of the deferred tax asset are as follows (in thousands): Schedule of Components of Deferred Tax Asset 2022 2021 Year Ended December 31, 2022 2021 Current accruals $ 859 $ 1,068 Operating lease liabilities 1,360 1,422 Deferred revenue 96 146 Depreciation and amortization 2,007 522 Deferred compensation 1,525 1,111 Net operating loss carryovers 27,629 27,219 Deferred tax assets 33,476 31,488 Valuation allowance (32,184 ) (30,101 ) Net deferred tax assets before deferred tax liabilities 1,292 1,387 Operating lease right-of-use assets (1,249 ) (1,334 ) Capitalized compensation costs (43 ) (53 ) Net deferred tax assets $ - $ - Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. In general, an “ownership change” will occur if there is a cumulative change in our ownership by “5-percent shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Following significant ownership changes during 2013, the Company initiated a review of the availability of its U.S. net operating loss carryforwards. As a result of this review, it was determined that a large portion of the Company’s net operating loss carryovers would expire unused due to the limitation under IRC Section 382. The Company reduced the net operating loss carryover and corresponding valuation allowance as a result of these limitations as reflected in the net operating loss carryovers in the table above. The remaining net operating loss carryforwards following the ownership change have been assigned a full valuation allowance against all deferred tax assets. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable losses, and projections for future periods over which the deferred tax assets are deductible, the Company determined that a 100% valuation allowance of deferred tax assets was appropriate. On December 21, 2020, Congress approved the Consolidations Appropriations Act, 2021 (the “Appropriations Act”), which was signed into law by the President on December 27, 2020. The Appropriations Act funded the federal government to the end of the fiscal year 2020 and provided further COVID-19 economic relief. One of the business provisions included in the Appropriations Act is clarification of the income tax deductibility of business expenses that were paid for with the Paycheck Protection Program funds. The Company will continue to monitor for additional legislation related to COVID-19 and its impact on our results of operations. As of December 31, 2022, we had gross federal net operating loss carryforwards of approximately $ 121.7 236.4 159.2 32.8 expire at various dates between 2023 and 2042 if not utilized The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. As the Company has a federal net operating loss carryforward from the year ended December 31, 2002 forward, all tax years from 2002 forward are subject to examination. As states have varying carryforward periods, and the Company has recently entered into additional states, the states are generally subject to examination for the previous 10 At December 31, 2022 and 2021, the Company had less than $ 0.1 0.1

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2022
Net loss per share attributable to common stockholders:
Net Loss per Share	12. Net Loss per Share The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations (in thousands): Schedule of Computation of Basic and Diluted Earnings Per Share 2022 2021 Year Ended December 31, 2022 2021 Net loss $ (18,292 ) $ (10,716 ) Cumulative dividend on convertible preferred stock (1,343 ) (1,345 ) Net loss attributable to common stockholders $ (19,635 ) $ (12,061 ) Weighted average number of common shares and equivalents: 76,061,183 75,558,233 Basic EPS $ (0.26 ) $ (0.16 ) Diluted EPS $ (0.26 ) $ (0.16 ) The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows: Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share December 31, 2022 2021 Shares issuable upon vesting/exercise of: Options to purchase common stock 3,208,065 2,818,012 Series A Convertible Preferred Stock and Accumulated Dividends 47,364,216 45,306,189 Series B Convertible Preferred Stock 5,610,121 5,610,121 Restricted stock units 1,208,739 1,164,723 57,391,141 54,899,045

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Employee Benefit Plan	13. Employee Benefit Plan The Company offers employees the opportunity to participate in a 401(k) plan and matches employee contributions up to 3% 0.3

Product Warranty Provisions

Product Warranty Provisions	12 Months Ended
	Dec. 31, 2022
Guarantees and Product Warranties [Abstract]
Product Warranty Provisions	14. Product Warranty Provisions The Company’s standard policy is to warrant all capital systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate. Accrued warranty, which is included in other accrued liabilities, consists of the following (in thousands): Schedule of Accrued Warranty December 31, 2022 December 31, 2021 Warranty accrual, beginning of the fiscal period $ 242 $ 158 Accrual adjustment for product warranty 113 199 Payments made (192 ) (115 ) Warranty accrual, end of the fiscal period $ 163 $ 242

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company. In April 2021, the Company entered into a letter of credit pursuant to the Lease agreement totaling approximately $ 1.8 and the fourth was delivered in January 2022.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Information	16. Segment Information The Company considers reporting segments in accordance with general accounting principles for disclosures about segments of an enterprise and related information. The Company’s system and disposable devices are developed and marketed to a broad base of hospitals in the United States and internationally. The Company considers all such sales to be part of a single operating segment. Geographic revenues for the years ended December 31, 2022 and 2021 were as follows (in thousands): Schedule of Geographic Revenues Year Ended December 31, 2022 2021 United States $ 19,708 $ 20,360 International 8,439 14,661 Total $ 28,147 $ 35,021 All of the Company’s long-lived assets are located in the United States. Revenues are attributed to countries based on the location of the customer.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events None.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”).
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand, money market instruments, and other highly liquid investments with original maturities of three months or less from the date of purchase.
Restricted Cash	Restricted Cash Restricted cash primarily consists of cash that the Company is obligated to maintain in accordance with contractual obligations.
Investments	Investments Our investments may include, at any time, a diversified portfolio of cash equivalents and short- and long-term investments in a variety of high-quality securities, including money market funds, U.S. treasury and U.S. government agency securities, corporate notes and bonds, commercial paper, non-U.S. government agency securities, and municipal notes. As of December 31, 2022, the Company’s short-term investments consisted of U.S. treasury securities and fixed maturity, marketable debt securities with original maturities at the time of purchase of one year or less, but greater than 90 days. These investments are classified as held to maturity. Securities classified as held to maturity are securities that the Company has the ability and intent to hold to maturity or redemption and are carried at amortized cost. Amortized cost of U.S. treasury securities and marketable debt securities are based on the Company’s purchase price adjusted for accrual of discount, or amortization of premium, and recognition of impairment charges, if any. The amortized cost of securities the Company purchases at a discount or premium will equal the face or par value at maturity or the call date, if applicable. Interest is reported as income when earned and is adjusted for amortization or accretion of any premium or discount. There were no impairments for the year ended December 31, 2022.
Fair Value Measurements	Fair Value Measurements Financial instruments consist of cash and cash equivalents, restricted cash, investments, accounts receivable, and accounts payable. The Company measures certain financial assets and liabilities at fair value on a recurring basis. General accounting principles for fair value measurement establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below: Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market. Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market. As of December 31, 2022, financial assets that are classified as Level 2 include money market funds, U.S. treasury securities and corporate debt securities. As of December 31, 2021, financial assets that are classified as Level 2 include money market funds. The Company reviews trading activity and pricing for these investments as of the measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. This approach results in the Level 2 classification of these securities within the fair value hierarchy.
Compensating Cash Arrangement	Compensating Cash Arrangement In July 2020, the Company entered into a letter of credit to support a commitment of less than $ 0.3 0.3
Accounts Receivable and Allowance for Uncollectible Accounts	Accounts Receivable and Allowance for Uncollectible Accounts Accounts receivable primarily include amounts due from hospitals and distributors for acquisition of magnetic systems, associated disposable device sales and service contracts. Credit is granted on a limited basis, with balances due generally within 30 days of billing. The provision for bad debts is based upon management’s assessment of historical and expected net collections considering business and economic conditions and other collection indicators.
Inventory	Inventory The Company values its inventory at the lower of cost, as determined using the first-in, first-out (FIFO) method, or net realizable value. The Company periodically reviews its physical inventory and provides a reserve upon identification of potential excess or obsolete items. Excess manufacturing overhead costs attributable to idle facility expenses or abnormally low production volumes are excluded from inventory and recorded as an expense in the period incurred.
Property and Equipment	Property and Equipment Property and equipment consist primarily of leasehold improvements, construction in process, computer, office, research and demonstration equipment, and equipment held for lease and are stated at cost. Depreciation is calculated using the straight-line method over the estimated useful lives or life of the base lease term, ranging from three to ten years.
Long-Lived Assets	Long-Lived Assets If facts and circumstances suggest that a long-lived asset may be impaired, the carrying value is reviewed. If this review indicates that the carrying value of the asset will not be recovered, as determined based on projected undiscounted cash flows related to the asset over its remaining life, the carrying value of the asset is reduced to its estimated fair value, which in most cases is estimated based upon Level 3 inputs.
Intangible Assets	Intangible Assets Intangible assets consist of purchased technology and intellectual property rights valued at cost on the acquisition date and amortized over their estimated useful lives of 10 15
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and loss during the reporting period. Actual results could differ from those estimates.
Revenue and Costs of Revenue	Revenue and Costs of Revenue Revenue Recognition The Company accounts for revenue in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), Revenue from Contracts with Customers We generate revenue from initial capital sales of systems as well as recurring revenue from the sale of our proprietary disposable devices, from royalties paid to the Company on the sale of various devices as provided by co-development and co-placement arrangements, and from revenue including ongoing software updates and service contracts. We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We record our revenue based on consideration specified in the contract with each customer, net of any taxes collected from customers that are remitted to government authorities. For contracts containing multiple products and services the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer. For arrangements with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services and market conditions. The Company regularly reviews standalone selling prices and updates these estimates if necessary. Our revenue recognition policy affects the following revenue streams in our business as follows: Systems: Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation and an implied obligation to provide software enhancements if and when available for one year following installation. Revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. Revenue from the implied obligation to deliver software enhancements if and when available is recognized ratably over the first year following installation of the system as the customer receives the right to software updates throughout the period and is included in Other Recurring Revenue. The Company’s system contracts generally do not provide a right of return. Systems are generally covered by a one-year assurance type warranty; warranty costs were approximately $ 0.1 0.2 24 32 Disposables: Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but can also occur at the time of delivery depending on the customer arrangement. Disposable products are covered by an assurance type warranty that provides for the return of defective products. Warranty costs were not material for the periods presented. Disposable revenue represented 28 24 Royalty: The Company received royalty payments from Biosense Webster, payable quarterly based on net revenues from sales of the co-developed catheters. Royalty revenue from the co-developed catheters represented 7 % of revenue for the years ended December 31, 2022 and 2021. Other Recurring Revenue: Other recurring revenue includes revenue from product maintenance plans, other post warranty maintenance, and the implied obligation to provide software enhancements if and when available for a specified period, typically one year following installation of our systems. Revenue from services and software enhancements is deferred and amortized over the service or update period, which is typically one year. Revenue related to services performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 41 34 Sublease Revenue: A portion of our principal executive office was subleased to a third party through 2021. In accordance with Accounting Standards Update (ASU) 2016-02, “Leases” (Topic 842), the Company recorded sublease income as revenue. Sublease revenue represented 3 The following table summarizes the Company’s revenue for systems, disposables, service and accessories and sublease for the years ended December 31, 2022 and 2021 (in thousands): Schedule of Revenue Disaggregated by Type 2022 2021 Year Ended December 31, 2022 2021 Systems $ 6,845 $ 11,168 Disposables, service and accessories 21,302 22,867 Sublease - 986 Total revenue $ 28,147 $ 35,021 Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to the Company’s systems contracts and obligations that will be recognized as revenue in future periods. These obligations are generally satisfied within two years after contract inception but may occasionally extend longer. Transaction price representing revenue to be earned on remaining performance obligations on system contracts was approximately $ 14.8 The following information summarizes the Company’s contract assets and liabilities (in thousands): Summary of Contract Assets and Liabilities December 31, 2022 December 31, 2021 Contract Assets - unbilled receivables $ 539 $ 178 Customer deposits $ 2,339 $ 925 Product shipped, revenue deferred 1,389 1,794 Deferred service and license fees 5,268 5,796 Total deferred revenue $ 8,996 $ 8,515 Less: Long-term deferred revenue (1,654 ) (2,238 ) Total current deferred revenue $ 7,342 $ 6,277 The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets primarily represent the difference between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Customer deposits primarily relate to future system sales but can also include deposits on disposable sales. Deferred revenue is primarily related to service contracts, for which the service fees are billed up-front, generally quarterly or annually, and for amounts billed in advance for system contracts for which some performance obligations remain outstanding. For service contracts, the associated deferred revenue is generally recognized ratably over the service period. For system contracts, the associated deferred revenue is recognized when the remaining performance obligations are satisfied. The Company did not have any impairment losses on its contract assets for the periods presented. Revenue recognized for the years ended December 31, 2022 and 2021, that was included in the deferred revenue balance at the beginning of each reporting period was $ 5.9 5.1 The Company has determined that sales incentive programs for the Company’s sales team meet the requirements to be capitalized as the Company expects to generate future economic benefits from the related revenue generating contracts after the initial capital sales transaction. The costs capitalized as contract acquisition costs included in prepaid expenses and other assets in the Company’s balance sheets were $ 0.2 Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.
Leasing Arrangements	Leasing Arrangements A lease is defined as a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. The Company accounts for leases in accordance with Accounting Standards Update No. 2016-02 “Leases” (Topic 842) and all subsequent ASUs that modified Topic 842 (“ASC 842”). The Company determines if an arrangement contains a lease at inception. The Company leases its facilities under operating leases. In accordance with ASC 842, operating lease agreements are recognized on the balance sheet as a right-of-use (“ROU”) asset and a corresponding lease liability. These leases generally do not have significant rent escalation holidays, concessions, leasehold improvement incentives, or other build-out clauses. Further, the leases do not contain contingent rent provisions. Many of our leases include both lease (i.e., fixed payments including rent, taxes, and insurance costs) and non-lease components (i.e., common-area or other maintenance costs) which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. A portion of our prior principal executive office was subleased to a third party through 2021. The sublease did not have significant rent escalation holidays, concessions, leasehold improvement incentives, or other build-out clauses. In addition, the sublease did not contain contingent rent provisions nor were there options to extend or terminate the sublease. The sublease ended December 31, 2021. The Company’s lease agreements often include one or more options to renew at the Company’s discretion. If at lease inception, the Company considers the exercising of a renewal option to be reasonably certain, the Company will include the extended term in the calculation of the ROU asset and lease liability. The Company elected not to include short-term leases (i.e., leases with initial terms of twelve months or less) on the balance sheet. The calculated amounts of the ROU assets and lease liabilities are impacted by the length of the lease term and the discount rate used to calculate the present value of the minimum lease payments. ASC 842 requires the use of the discount rate implicit in the lease whenever this rate is readily determinable. As this rate is rarely determinable, the Company utilizes its incremental borrowing rate at lease inception.
Research and Development Costs	Research and Development Costs Internal research and development costs are expensed in the period incurred. Amounts receivable from strategic relationships under research reimbursement agreements are recorded as a contra-research and development expense in the period reimbursable costs are incurred. There were no material receivables as of December 31, 2022 or 2021 under these types of agreements. Advance receipts or other unearned reimbursements are included in accrued liabilities on the accompanying balance sheet until earned.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the stock-based compensation at the grant date and the recognition of the related expense over the period in which the stock-based compensation vests. For time-based awards, the Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The weighted average assumptions and fair value for options granted during the year ended December 31, 2022, were 1) expected dividend rate of 0 80 6.25 For market-based awards, stock-based compensation expense is recognized over the minimum service period regardless of whether or not the market target is probable of being achieved. The fair value of such awards is estimated on the grant date using Monte Carlo simulations. Shares purchased by employees under the 2022 Employee Stock Purchase Plan are considered to be non-compensatory.
Net Loss per Common Share	Net Loss per Common Share Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our convertible preferred stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our convertible preferred stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our convertible preferred stock issued and outstanding during the period, except where the effect of such securities would be antidilutive. The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses. As of December 31, 2022, the Company had 3,208,065 4.21 47,364,216 5,610,121 1,208,739
Income Taxes	Income Taxes In accordance with general accounting principles for income taxes ,
Product Warranty Provisions	Product Warranty Provisions The Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability (included in other accrued liabilities) as appropriate.
Patent Costs	Patent Costs Costs related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
Concentrations of Risk	Concentrations of Risk The majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the U.S. Deposits in this institution exceed the amount of government provided insurance on such deposits. No single customer accounted for more than 10% of total revenue for the years ended December 31, 2022 and 2021. Revenue from customers in China accounted for $ 3.7 10
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments” and also issued subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04 and ASU 2019-05. The standard modifies the measurement approach for credit losses on financial instruments, including trade receivables, from an incurred loss method to a current expected credit loss method, otherwise known as “CECL.” The standard requires the measurement of expected credit losses to be based on relevant information, including historical experience, current conditions and a forecast that is supportable. The standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years; early adoption is permitted. The standard must be adopted by applying a cumulative adjustment to retained earnings. The Company anticipates adopting the standard in the first quarter of 2023, although it does not expect a significant impact to the Company’s financial results.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Revenue Disaggregated by Type	The following table summarizes the Company’s revenue for systems, disposables, service and accessories and sublease for the years ended December 31, 2022 and 2021 (in thousands): Schedule of Revenue Disaggregated by Type 2022 2021 Year Ended December 31, 2022 2021 Systems $ 6,845 $ 11,168 Disposables, service and accessories 21,302 22,867 Sublease - 986 Total revenue $ 28,147 $ 35,021
Summary of Contract Assets and Liabilities	The following information summarizes the Company’s contract assets and liabilities (in thousands): Summary of Contract Assets and Liabilities December 31, 2022 December 31, 2021 Contract Assets - unbilled receivables $ 539 $ 178 Customer deposits $ 2,339 $ 925 Product shipped, revenue deferred 1,389 1,794 Deferred service and license fees 5,268 5,796 Total deferred revenue $ 8,996 $ 8,515 Less: Long-term deferred revenue (1,654 ) (2,238 ) Total current deferred revenue $ 7,342 $ 6,277

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Schedule of Cash and Held to Maturity Securities	The following table summarizes the Company’s cash and held to maturity securities’ amortized cost, gross unrealized gains, gross unrealized losses, and fair value by significant investment category reported as cash and cash equivalents, restricted cash and investments as of December 31, 2022, and 2021: Schedule of Cash and Held to Maturity Securities December 31, 2022 Valuation Balance Sheet Classification (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Restricted Cash- current Short-term Investments Restricted Cash Cash $ 3,258 $ - $ - $ 3,258 $ 3,258 $ - $ - $ - Level 2 Money market funds 1,615 - - 1,615 346 525 - 744 US treasury securities 14,833 2 (2 ) 14,833 4,982 - 9,851 - Corporate debt securities 9,993 - (6 ) 9,987 - - 9,993 - Subtotal 26,441 2 (8 ) 26,435 5,328 525 19,844 744 Total assets measured at fair value $ 29,699 $ 2 $ (8 ) $ 29,693 $ 8,586 $ 525 $ 19,844 $ 744 December 31, 2021 Valuation Balance Sheet Classification (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Restricted Cash- current Short-term Investments Restricted Cash Cash $ 38,739 $ - $ - $ 38,739 $ 38,739 $ - $ - $ - Level 2 Money market funds 1,405 - - 1,405 - 453 - 952 Subtotal 1,405 - - 1,405 - 453 - 952 Total assets measured at fair value $ 40,144 $ - $ - $ 40,144 $ 38,739 $ 453 $ - $ 952

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventory consists of the following (in thousands): Schedule of Inventories December 31, 2022 December 31, 2021 Raw materials $ 6,556 $ 3,642 Work in process 530 133 Finished goods 2,697 2,823 Reserve for excess and obsolescence (1,907 ) (2,165 ) Total inventory $ 7,876 $ 4,433

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Assets	Prepaid expenses and other assets consist of the following (in thousands): Schedule of Prepaid Expenses and Other Assets December 31, 2022 December 31, 2021 Prepaid expenses $ 605 $ 1,012 Prepaid commissions 187 229 Deposits 669 1,276 Other assets 72 117 Total prepaid expenses and other assets 1,533 2,634 Less: Noncurrent prepaid expenses and other assets (208 ) (278 ) Total current prepaid expenses and other assets $ 1,325 $ 2,356

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): Schedule of Property and Equipment December 31, 2022 December 31, 2021 Equipment $ 4,393 $ 3,670 Leasehold improvements 2,692 17 Construction in process 204 2,156 Gross property and equipment 7,289 5,843 Less: Accumulated depreciation (3,458 ) (3,211 ) Net property and equipment $ 3,831 $ 2,632

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases
Schedule of Lease Costs and Other Lease Information	The following table represents lease costs and other lease information (in thousands): Schedule of Lease Costs and Other Lease Information 2022 2021 Year Ended December 31, 2022 2021 Operating lease cost $ 909 $ 2,707 Short-term lease cost 28 57 Sublease income - (986 ) Total net lease cost $ 937 $ 1,778 Cash paid within operating cash flows $ 886 $ 2,223
Schedule of Future Minimum Operating Lease Payments	Future minimum payments for operating leases with initial or remaining terms of one year or more as of December 31, 2022, were as follows (in thousands): Schedule of Future Minimum Operating Lease Payments December 31, 2022 2023 $ 877 2024 898 2025 919 2026 935 2027 956 2028 and thereafter 4,030 Total lease payments $ 8,615 Less: Interest (2,754 ) Present value of lease liabilities $ 5,861

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): Schedule of Accrued Liabilities December 31, 2022 December 31, 2021 Accrued salaries, bonus, and benefits $ 1,381 $ 1,516 Accrued licenses and maintenance fees 484 484 Accrued warranties 163 242 Accrued taxes 47 177 Accrued investigational sites 101 123 Accrued lease deposit payable - 124 Deferred contract obligation 1,045 - Other 136 80 Total accrued liabilities 3,357 2,746 Less: Long term accrued liabilities (51 ) (218 ) Total current accrued liabilities $ 3,306 $ 2,528

Convertible Preferred Stock a_2

Convertible Preferred Stock and Stockholders’ Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Summary of Performance Award And Market Capitalization Milestones	Summary of Performance Award And Market Capitalization Milestones Tranche # No. of Shares Subject to PSU Market Capitalization Milestones 1 1,000,000 $ 1,000,000,000 2 1,500,000 $ 1,500,000,000 3 1,500,000 $ 2,000,000,000 4 2,000,000 $ 2,500,000,000 5 1,000,000 $ 3,000,000,000 6 1,000,000 $ 3,500,000,000 7 1,000,000 $ 4,000,000,000 8 2,000,000 $ 4,500,000,000 9 1,000,000 $ 5,000,000,000 10 1,000,000 $ 5,500,000,000 Total: 13,000,000
Summary of Option and Stock Appreciation Rights Activity	A summary of the option and stock appreciation rights activity for the year ended December 31, 2022 is as follows: Summary of Option and Stock Appreciation Rights Activity Number of Options/SARs Range of Exercise Price Weighted Average Exercise Price per Share Outstanding, December 31, 2021 2,818,012 $ 0.74 9.87 $ 4.10 Granted 843,500 $ 2.09 5.21 $ 4.49 Exercised (131,375 ) $ 0.74 4.52 $ 1.48 Forfeited (322,072 ) $ 0.74 7.70 $ 5.09 Outstanding, December 31, 2022 3,208,065 $ 0.74 9.87 $ 4.21
Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price	A summary of the options and stock appreciation rights outstanding by range of exercise price is as follows: Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price Year Ended December 31, 2022 Number of Weighted Weighted Weighted Options Average Exercise Options Average Average Currently Price Per Vested Range of Exercise Prices Outstanding Remaining Life Exercise Price Exercisable Share $ 0.00 1.00 345,364 5.16 $ 0.74 345,364 $ 0.74 $ 1.01 2.00 84,995 9.35 $ 1.59 7,995 $ 1.19 $ 2.01 4.00 631,339 5.99 $ 2.08 578,202 $ 2.07 $ 4.01 10.00 2,146,367 8.10 $ 5.50 817,736 $ 5.52 3,208,065 7.40 $ 4.21 1,749,297 $ 3.42
Summary of Restricted Stock Unit Activity	A summary of the restricted stock unit activity for the year ended December 31, 2022 is as follows: Summary of Restricted Stock Unit Activity Number of Restricted Stock Units Weighted Average Grant Date Fair Value per Unit Outstanding, December 31, 2021 1,164,723 $ 3.57 Granted 154,742 $ 7.68 Vested (110,726 ) $ 2.27 Outstanding, December 31, 2022 1,208,739 $ 4.21
Summary of Reserved Shares of Common Stock for Conversion	The Company has reserved shares of common stock for conversion of convertible preferred stock, and the issuance of options granted under the Company’s stock option plan and its stock purchase plan as follows: Summary of Reserved Shares of Common Stock for Conversion December 31, 2022 December 31, 2021 Series A Convertible Preferred Stock 45,023,612 45,031,944 Series B Convertible Preferred Stock 5,610,121 5,610,121 Performance Share Unit Plan 13,000,000 13,000,000 Stock award plans 3,930,952 4,909,848 Employee Stock Purchase Plan 164,654 209,437 Reserved shares of common stock 67,729,339 68,761,350

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Provision For Income Taxes	The provision for income taxes consists of the following (in thousands): Schedule of Provision For Income Taxes 2022 2021 Year Ended December 31, 2022 2021 Deferred: Federal $ (1,990 ) $ (1,723 ) State and local (93 ) 1 Total deferred income tax expense (benefit) (2,083 ) (1,722 ) Valuation allowance 2,083 1,722 Income tax benefit $ — $ —
Schedule of Reconciliation of Federal Income Tax Rate	The provision for income taxes varies from the amount determined by applying the U.S. federal statutory rate to income before income taxes as a result of the following: Schedule of Reconciliation of Federal Income Tax Rate 2022 2021 Year Ended December 31, 2022 2021 U.S. statutory income tax rate 21.0 % 21.0 % State and local taxes, net of federal tax benefit 1.1 % 1.4 % Stock compensation permanent differences between book and tax (7.1 )% (10.1 )% Other permanent differences between book and tax (3.0 )% 5.3 % State rate adjustments (0.6 )% (1.5 )% Valuation allowance (11.4 )% (16.1 )% Effective income tax rate — % — %
Schedule of Components of Deferred Tax Asset	The components of the deferred tax asset are as follows (in thousands): Schedule of Components of Deferred Tax Asset 2022 2021 Year Ended December 31, 2022 2021 Current accruals $ 859 $ 1,068 Operating lease liabilities 1,360 1,422 Deferred revenue 96 146 Depreciation and amortization 2,007 522 Deferred compensation 1,525 1,111 Net operating loss carryovers 27,629 27,219 Deferred tax assets 33,476 31,488 Valuation allowance (32,184 ) (30,101 ) Net deferred tax assets before deferred tax liabilities 1,292 1,387 Operating lease right-of-use assets (1,249 ) (1,334 ) Capitalized compensation costs (43 ) (53 ) Net deferred tax assets $ - $ -

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Net loss per share attributable to common stockholders:
Schedule of Computation of Basic and Diluted Earnings Per Share	The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted earnings per share calculations (in thousands): Schedule of Computation of Basic and Diluted Earnings Per Share 2022 2021 Year Ended December 31, 2022 2021 Net loss $ (18,292 ) $ (10,716 ) Cumulative dividend on convertible preferred stock (1,343 ) (1,345 ) Net loss attributable to common stockholders $ (19,635 ) $ (12,061 ) Weighted average number of common shares and equivalents: 76,061,183 75,558,233 Basic EPS $ (0.26 ) $ (0.16 ) Diluted EPS $ (0.26 ) $ (0.16 )
Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share	The following table sets forth the number of common shares that were excluded from the computation of diluted earnings per share because their inclusion would have been anti-dilutive as follows: Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share December 31, 2022 2021 Shares issuable upon vesting/exercise of: Options to purchase common stock 3,208,065 2,818,012 Series A Convertible Preferred Stock and Accumulated Dividends 47,364,216 45,306,189 Series B Convertible Preferred Stock 5,610,121 5,610,121 Restricted stock units 1,208,739 1,164,723 57,391,141 54,899,045

Product Warranty Provisions (Ta

Product Warranty Provisions (Tables)	12 Months Ended
	Dec. 31, 2022
Guarantees and Product Warranties [Abstract]
Schedule of Accrued Warranty	Accrued warranty, which is included in other accrued liabilities, consists of the following (in thousands): Schedule of Accrued Warranty December 31, 2022 December 31, 2021 Warranty accrual, beginning of the fiscal period $ 242 $ 158 Accrual adjustment for product warranty 113 199 Payments made (192 ) (115 ) Warranty accrual, end of the fiscal period $ 163 $ 242

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Schedule of Geographic Revenues	Schedule of Geographic Revenues Year Ended December 31, 2022 2021 United States $ 19,708 $ 20,360 International 8,439 14,661 Total $ 28,147 $ 35,021

Schedule of Revenue Disaggregat

Schedule of Revenue Disaggregated by Type (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Product Information [Line Items]
Total revenue	$ 28,147	$ 35,021
Systems [Member]
Product Information [Line Items]
Total revenue	6,845	11,168
Disposables Service And Accessories [Member]
Product Information [Line Items]
Total revenue	21,302	22,867
Sublease [Member]
Product Information [Line Items]
Total revenue		$ 986

Summary of Contract Assets and

Summary of Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Product Information [Line Items]
Contract Assets - unbilled receivables	$ 539	$ 178
Total deferred revenue	8,996	8,515
Less: Long-term deferred revenue	(1,654)	(2,238)
Total current deferred revenue	7,342	6,277
Customer Deposits [Member]
Product Information [Line Items]
Total deferred revenue	2,339	925
Product Shipped Revenue Deferred [Member]
Product Information [Line Items]
Total deferred revenue	1,389	1,794
Deferred Service And License Fees [Member]
Product Information [Line Items]
Total deferred revenue	$ 5,268	$ 5,796

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jul. 31, 2020
Product Information [Line Items]
Remaining performance obligation	$ 14,800
Contract with customer liability revenue recognized	5,900	$ 5,100
Capitalized contract cost	$ 200	$ 200
Expected dividend rate	0%
Expected volatility	80%
Expected term	6 years 3 months
Potential common shares excluded from diluted earnings per share	57,391,141	54,899,045
Weighted average exercise price	$ 4.21	$ 4.10
Total revenue	$ 28,147	$ 35,021
Series B Convertible Preferred Stock [Member]
Product Information [Line Items]
Potential common shares excluded from diluted earnings per share	5,610,121
Series A Convertible Preferred Stock [Member]
Product Information [Line Items]
Potential common shares excluded from diluted earnings per share	47,364,216
Stock Options and Stock Appreciation Rights [Member]
Product Information [Line Items]
Potential common shares excluded from diluted earnings per share	3,208,065
Weighted average exercise price	$ 4.21
Restricted Stock [Member]
Product Information [Line Items]
Number of unvested restricted share units	1,208,739
Revenue From System Delivery and Installation [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage	24%	32%
Disposable Revenue [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage	28%	24%
Royalty Revenue [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage	7%	7%
Other Recurring Revenue [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage	41%	34%
Sublease Revenue [Member] | Product Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage		3%
Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member] | China Customer [Member]
Product Information [Line Items]
Total revenue		$ 3,700
Concentration risk percentage		10%
Systems [Member]
Product Information [Line Items]
Product Warranty Expense	$ 100	$ 200
Total revenue	$ 6,845	$ 11,168
Maximum [Member]
Product Information [Line Items]
Intangible assets, estimated useful lives	15 years
Minimum [Member]
Product Information [Line Items]
Intangible assets, estimated useful lives	10 years
Letter of Credit [Member]
Product Information [Line Items]
Compensating balance, amount			$ 300
Letter of Credit [Member] | Maximum [Member]
Product Information [Line Items]
Line of credit, current			$ 300

Schedule of Cash and Held to Ma

Schedule of Cash and Held to Maturity Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Cash	$ 3,258	$ 38,739
Total assets measured at fair value, Amortized Cost	29,699	40,144
Total assets measured at fair value, Gross Unrealized Gains	2
Total assets measured at fair value, Gross Unrealized Losses	8
Total assets measured at fair value, Fair Value	29,693	40,144
Total assets measured at fair value, Cash and Cash Equivalents	8,586	38,739
Total assets measured at fair value, Restricted Cash, Current	525	453
Total assets measured at fair value, Short-Term Investments	19,844
Total assets measured at fair value, Restricted Cash, Noncurrent	744	952
Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss	(8)
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total assets measured at fair value, Amortized Cost	1,615	1,405
Total assets measured at fair value, Gross Unrealized Gains
Total assets measured at fair value, Gross Unrealized Losses
Total assets measured at fair value, Fair Value	1,615	1,405
Total assets measured at fair value, Cash and Cash Equivalents	346
Total assets measured at fair value, Restricted Cash, Current	525	453
Total assets measured at fair value, Short-Term Investments
Total assets measured at fair value, Restricted Cash, Noncurrent	744	952
Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total assets measured at fair value, Amortized Cost	14,833
Total assets measured at fair value, Gross Unrealized Gains	2
Total assets measured at fair value, Gross Unrealized Losses	2
Total assets measured at fair value, Fair Value	14,833
Total assets measured at fair value, Cash and Cash Equivalents	4,982
Total assets measured at fair value, Restricted Cash, Current
Total assets measured at fair value, Short-Term Investments	9,851
Total assets measured at fair value, Restricted Cash, Noncurrent
Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss	(2)
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total assets measured at fair value, Amortized Cost	9,993
Total assets measured at fair value, Gross Unrealized Gains
Total assets measured at fair value, Gross Unrealized Losses	6
Total assets measured at fair value, Fair Value	9,987
Total assets measured at fair value, Cash and Cash Equivalents
Total assets measured at fair value, Restricted Cash, Current
Total assets measured at fair value, Short-Term Investments	9,993
Total assets measured at fair value, Restricted Cash, Noncurrent
Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss	(6)
Subtotal [Member] | Fair Value, Inputs, Level 2 [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total assets measured at fair value, Amortized Cost	26,441	1,405
Total assets measured at fair value, Gross Unrealized Gains	2
Total assets measured at fair value, Gross Unrealized Losses	8
Total assets measured at fair value, Fair Value	26,435	1,405
Total assets measured at fair value, Cash and Cash Equivalents	5,328
Total assets measured at fair value, Restricted Cash, Current	525	453
Total assets measured at fair value, Short-Term Investments	19,844
Total assets measured at fair value, Restricted Cash, Noncurrent	744	952
Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss	$ (8)

Financial Instruments (Details

Financial Instruments (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Impairment Effects on Earnings Per Share [Line Items]
Interest income	$ 484	$ (11)
Investments [Member]
Impairment Effects on Earnings Per Share [Line Items]
Interest income	$ 500	$ 100

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 6,556	$ 3,642
Work in process	530	133
Finished goods	2,697	2,823
Reserve for excess and obsolescence	(1,907)	(2,165)
Total inventory	$ 7,876	$ 4,433

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 605	$ 1,012
Prepaid commissions	187	229
Deposits	669	1,276
Other assets	72	117
Total prepaid expenses and other assets	1,533	2,634
Less: Noncurrent prepaid expenses and other assets	(208)	(278)
Total current prepaid expenses and other assets	$ 1,325	$ 2,356

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 7,289	$ 5,843
Less: Accumulated depreciation	(3,458)	(3,211)
Net property and equipment	3,831	2,632
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	4,393	3,670
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	2,692	17
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 204	$ 2,156

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Disposals of fixed assets	$ 0.2	$ 5.5
Property and equipment additions	$ 1.2	$ 2.5

Schedule of Lease Costs and Oth

Schedule of Lease Costs and Other Lease Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases
Operating lease cost	$ 909	$ 2,707
Short-term lease cost	28	57
Sublease income		(986)
Total net lease cost	937	1,778
Cash paid within operating cash flows	$ 886	$ 2,223

Schedule of Future Minimum Oper

Schedule of Future Minimum Operating Lease Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2021
Leases
2023	$ 877
2024	898
2025	919
2026	935
2027	956
2028 and thereafter	4,030
Total lease payments	8,615
Less: Interest	(2,754)
Present value of lease liabilities	$ 5,861	$ 5,900

Leases (Details Narrative)

Leases (Details Narrative) $ in Thousands	Mar. 01, 2021 USD ($) ft²	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease liability		$ 5,861		$ 5,900
Operating lease, right-of-use asset		$ 5,384	$ 5,736	$ 5,900
Weighted average discount rate, operating lease		9%
Weighted average remaining lease term, operating lease		8 years 11 months 26 days
Office Lease Agreement [Member] | Globe Building Company [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Area of land | ft²	43,100
Operating lease, term	10 years
Operating lease, option to extend	two
Operating lease, renewal term	5 years
Office Lease Agreement [Member] | Globe Building Company [Member] | 2022 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent	$ 800
Office Lease Agreement [Member] | Globe Building Company [Member] | 2031 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for rent	$ 1,000

Schedule of Accrued Liabilities

Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued salaries, bonus, and benefits	$ 1,381	$ 1,516
Accrued licenses and maintenance fees	484	484
Accrued warranties	163	242
Accrued taxes	47	177
Accrued investigational sites	101	123
Accrued lease deposit payable		124
Deferred contract obligation	1,045
Other	136	80
Total accrued liabilities	3,357	2,746
Less: Long term accrued liabilities	(51)	(218)
Total current accrued liabilities	$ 3,306	$ 2,528

Debt and Credit Facilities (Det

Debt and Credit Facilities (Details Narrative) - USD ($) $ in Thousands		12 Months Ended
	Apr. 20, 2020	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Gain on extinguishment of debt			$ 2,183
Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Proceed from bank loan	$ 2,200
Gain on extinguishment of debt		$ 2,200

Summary of Performance Award An

Summary of Performance Award And Market Capitalization Milestones (Details) - PSU Agreement [Member] - Mr. Fischel [Member]	Feb. 23, 2021 USD ($) shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	13,000,000
Market capitalization milestone, amount | $	$ 1,000,000,000
Share-Based Payment Arrangement, Tranche One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 1,000,000,000
Share-Based Payment Arrangement, Tranche Two [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,500,000
Market capitalization milestone, amount | $	$ 1,500,000,000
Share-Based Payment Arrangement, Tranche Three [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,500,000
Market capitalization milestone, amount | $	$ 2,000,000,000
ShareBased Compensation Award Tranche Four [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	2,000,000
Market capitalization milestone, amount | $	$ 2,500,000,000
ShareBased Compensation Award Tranche Five [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 3,000,000,000
ShareBased Compensation Award Tranche Six [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 3,500,000,000
ShareBased Compensation Award Tranche Seven [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 4,000,000,000
ShareBased Compensation Award Tranche Eight [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	2,000,000
Market capitalization milestone, amount | $	$ 4,500,000,000
ShareBased Compensation Award Tranche Nine [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 5,000,000,000
ShareBased Compensation Award Tranche Ten [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares subject to PSU | shares	1,000,000
Market capitalization milestone, amount | $	$ 5,500,000,000

Summary of Option and Stock App

Summary of Option and Stock Appreciation Rights Activity (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Number of Options/SARs, Outstanding, Beginning | shares	2,818,012
Weighted Average Exercise Price per Share, Outstanding, Beginning	$ 4.10
Number of Options/SARs, Granted | shares	843,500
Weighted Average Exercise Price per Share, Granted	$ 4.49
Number of Options/SARs, Exercised | shares	(131,375)
Weighted Average Exercise Price per Share, Exercised	$ 1.48
Number of Options/SARs, Forfeited | shares	(322,072)
Weighted Average Exercise Price per Share, Forfeited	$ 5.09
Number of Options/SARs, Outstanding, Ending | shares	3,208,065
Weighted Average Exercise Price per Share, Outstanding, Ending	$ 4.21
Minimum [Member]
Range of Exercise Price, Outstanding, Beginning	0.74
Range of Exercise Price, Granted	2.09
Range of Exercise Price, Exercised	0.74
Range of Exercise Price, Forfeited	0.74
Range of Exercise Price, Outstanding, Ending	0.74
Maximum [Member]
Range of Exercise Price, Outstanding, Beginning	9.87
Range of Exercise Price, Granted	5.21
Range of Exercise Price, Exercised	4.52
Range of Exercise Price, Forfeited	7.70
Range of Exercise Price, Outstanding, Ending	$ 9.87

Summary of Option and Stock A_2

Summary of Option and Stock Appreciation Rights Outstanding by Range of Exercise Price (Details) - Stock Option and Stock Appreciation Rights (SARs) [Member]	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options Outstanding | shares	3,208,065
Weighted Average Remaining Life	7 years 4 months 24 days
Weighted Average Exercise Price	$ 4.21
Number of Options Currently Exercisable | shares	1,749,297
Weighted Average Exercise Price per Vested Share	$ 3.42
Range of Exercise Prices One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	0
Range of Exercise Prices, Upper Limit	$ 1
Options Outstanding | shares	345,364
Weighted Average Remaining Life	5 years 1 month 28 days
Weighted Average Exercise Price	$ 0.74
Number of Options Currently Exercisable | shares	345,364
Weighted Average Exercise Price per Vested Share	$ 0.74
Range of Exercise Prices Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	1.01
Range of Exercise Prices, Upper Limit	$ 2
Options Outstanding | shares	84,995
Weighted Average Remaining Life	9 years 4 months 6 days
Weighted Average Exercise Price	$ 1.59
Number of Options Currently Exercisable | shares	7,995
Weighted Average Exercise Price per Vested Share	$ 1.19
Range of Exercise Prices Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	2.01
Range of Exercise Prices, Upper Limit	$ 4
Options Outstanding | shares	631,339
Weighted Average Remaining Life	5 years 11 months 26 days
Weighted Average Exercise Price	$ 2.08
Number of Options Currently Exercisable | shares	578,202
Weighted Average Exercise Price per Vested Share	$ 2.07
Range of Exercise Prices Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices, Lower Limit	4.01
Range of Exercise Prices, Upper Limit	$ 10
Options Outstanding | shares	2,146,367
Weighted Average Remaining Life	8 years 1 month 6 days
Weighted Average Exercise Price	$ 5.50
Number of Options Currently Exercisable | shares	817,736
Weighted Average Exercise Price per Vested Share	$ 5.52

Summary of Restricted Stock Uni

Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, Beginning | shares	1,164,723
Weighted Average Grant Date Fair Value per Unit, Outstanding, Beginning | $ / shares	$ 3.57
Number of Restricted Stock Units, Outstanding, Granted | shares	154,742
Weighted Average Grant Date Fair Value per Unit, Granted | $ / shares	$ 7.68
Number of Restricted Stock Units, Outstanding, Vested | shares	(110,726)
Weighted Average Grant Date Fair Value per Unit, Vested | $ / shares	$ 2.27
Number of Restricted Stock Units, Outstanding, Ending | shares	1,208,739
Weighted Average Grant Date Fair Value per Unit, Outstanding, Ending | $ / shares	$ 4.21

Summary of Reserved Shares of C

Summary of Reserved Shares of Common Stock for Conversion (Details) - shares	Dec. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Reserved shares of common stock	67,729,339	68,761,350
Performance Share Unit Plan [Member]
Class of Stock [Line Items]
Reserved shares of common stock	13,000,000	13,000,000
Stock Award Plans [Member]
Class of Stock [Line Items]
Reserved shares of common stock	3,930,952	4,909,848
Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
Reserved shares of common stock	164,654	209,437
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Reserved shares of common stock	45,023,612	45,031,944
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Reserved shares of common stock	5,610,121	5,610,121

Convertible Preferred Stock a_3

Convertible Preferred Stock and Stockholders’ Equity (Details Narrative) - USD ($)			1 Months Ended	12 Months Ended
	Feb. 23, 2021	Aug. 07, 2019	Sep. 30, 2016	Dec. 31, 2022	Dec. 31, 2021	Sep. 29, 2021	Mar. 05, 2018	Feb. 28, 2018
Subsidiary, Sale of Stock [Line Items]
Common stock, voting rights				The holders of common stock are entitled to one vote for each share held
Payments of dividends common stock				$ 0
Preferred stock, par value				$ 0.001	$ 0.001
Stock-based compensation expense				$ 10,576,000	$ 9,363,000
Unrecognized stock-based compensation expense				$ 4,700,000
Common Stock, Capital Shares Reserved for Future Issuance				67,729,339	68,761,350
Share based payment arrangement, cost not yet recognized, period				4 years
Number of options and stock appreciation rights outstanding				3,208,065	2,818,012
Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares granted				154,742
2022 Stock Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Stock plan effective date				May 19, 2022
2022 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Subsidiary, Sale of Stock [Line Items]
Share vesting percentage				25%
Stock vesting period				3 years
2022 Stock Incentive Plan [Member] | Stock Appreciation Rights (SARs) [Member]
Subsidiary, Sale of Stock [Line Items]
Share expiration period				10 years
Share vesting percentage				25%
Stock vesting period				3 years
2022 Stock Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Stock vesting period				4 years
Aggregate intrinsic value, outstanding				$ 2,500,000
Aggregate intrinsic value, vested				$ 300,000
2022 Stock Incentive Plan [Member] | Stock Options and Stock Appreciation Rights (SARs) [Member]
Subsidiary, Sale of Stock [Line Items]
Contractual term				7 years 4 months 24 days
Number of options and stock appreciation rights outstanding				3,208,065
Number of options and stock appreciation rights, Exercisable, Number				1,749,297
Number of options and stock appreciation rights, weighted average exercise price				$ 3.42
Number of options and stock appreciation rights remaining contractual term				6 years 5 months 12 days
Outstanding, intrinsic value				$ 500,000
Share Price				$ 2.07
Options number of shares vested				881,207
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value				$ 100,000
Options grants weighted average grant date fair value				$ 4.49
Stock Award Plans [Member]
Subsidiary, Sale of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance				3,930,952	4,909,848
2012 Stock Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Subsidiary, Sale of Stock [Line Items]
Aggregate intrinsic value, outstanding					$ 7,200,000
2012 Stock Incentive Plan [Member] | Stock Options and Stock Appreciation Rights (SARs) [Member]
Subsidiary, Sale of Stock [Line Items]
Outstanding, intrinsic value					$ 6,600,000
Share Price					$ 6.20
Options number of shares vested					1,229,610
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value					$ 1,900,000
Options grants weighted average grant date fair value					$ 7.10
2022 Employee Stock Purchase Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance				164,654
Maximum purchase percentage of employees compensation				15%
Maximum fair value of shares subject to repurchase obligation				$ 25,000
Maximum fair value percentage of shares subject to repurchase obligation				95%
Employees Directors And Third Party Consultants [Member] | 2022 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Subsidiary, Sale of Stock [Line Items]
Share expiration period				10 years
Purchase Price of common stock, percent				100%
Non-employee Directors [Member] | 2022 Stock Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Subsidiary, Sale of Stock [Line Items]
Share expiration period				10 years
Purchase Price of common stock, percent				100%
Director [Member] | Maximum [Member] | 2022 Stock Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Stock vesting period				5 years
Director [Member] | Minimum [Member] | 2022 Stock Incentive Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Stock vesting period				1 year
PSU Agreement [Member] | Mr. Fischel [Member]
Subsidiary, Sale of Stock [Line Items]
Performance award term	10 years
Number of shares granted	13,000,000
Maximum market capitalization milestone, amount	$ 1,000,000,000
Increase in market capitalization milestone, amount	$ 500,000,000
Award vesting rights, description	Each tranche represents a portion of the PSUs covering the number of shares outlined in the table above. Each tranche vests upon (i) satisfaction of the market capitalization milestones and (ii) continued employment as CEO of the Company from the grant date through December 31, 2030. Absent an earlier termination, the PSUs will expire on December 31, 2030. If our CEO ceases employment as CEO of the Company for any reason including death, disability, termination for cause or without cause (as defined in the award agreement), or if he voluntary terminates after service as CEO for at least five years, the remaining service period will be waived and he will retain any PSUs that have vested through the date of termination
Stock-based compensation expense				$ 7,100,000	$ 6,100,000
Unrecognized stock-based compensation expense				$ 44,100,000	$ 51,300,000
PSU Agreement [Member] | Mr. Fischel [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Maximum market capitalization milestone, amount	$ 5,500,000,000
Series A Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares sold			24,000
Preferred stock, par value			$ 0.001
Preferred stock, stated value			1,000
Redemption price per share			$ 0.65				$ 0.28	$ 0.70
Common stock issuable from warrants			36,923,078
Preferred stock dividend rate			6%
Preferred stock redemption, triggering event, percent of common stock sold threshold			50%
Common Stock, Capital Shares Reserved for Future Issuance				45,023,612	45,031,944
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Unexercised warrants						15,385
Private Placement [Member] | Series B Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares sold		5,610,121
Preferred stock, par value		$ 0.001
Preferred Stock, Convertible, Conversion Price		$ 2.05

Schedule of Provision For Incom

Schedule of Provision For Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal	$ (1,990)	$ (1,723)
State and local	(93)	1
Total deferred income tax expense (benefit)	(2,083)	(1,722)
Valuation allowance	2,083	1,722
Income tax benefit

Schedule of Reconciliation of F

Schedule of Reconciliation of Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
U.S. statutory income tax rate	21%	21%
State and local taxes, net of federal tax benefit	1.10%	1.40%
Stock compensation permanent differences between book and tax	(7.10%)	(10.10%)
Other permanent differences between book and tax	(3.00%)	5.30%
State rate adjustments	(0.60%)	(1.50%)
Valuation allowance	(11.40%)	(16.10%)
Effective income tax rate

Schedule of Components of Defer

Schedule of Components of Deferred Tax Asset (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Current accruals	$ 859	$ 1,068
Operating lease liabilities	1,360	1,422
Deferred revenue	96	146
Depreciation and amortization	2,007	522
Deferred compensation	1,525	1,111
Net operating loss carryovers	27,629	27,219
Deferred tax assets	33,476	31,488
Valuation allowance	(32,184)	(30,101)
Net deferred tax assets before deferred tax liabilities	1,292	1,387
Operating lease right-of-use assets	(1,249)	(1,334)
Capitalized compensation costs	(43)	(53)
Net deferred tax assets

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Employee benefits and share-based compensation	$ 7.1	$ 6.1
Operating loss carryforwards	121.7
Operating loss carry forwards	159.2
Accrued interest and penalties	0.1	0.1
Maximum [Member]
Operating Loss Carryforwards [Line Items]
Reserves for uncertain tax positions	0.1	$ 0.1
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards	236.4
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards	$ 32.8
Operating loss carryforwards limitations on use	expire at various dates between 2023 and 2042 if not utilized
Number of prior years subject to examination	10 years

Schedule of Computation of Basi

Schedule of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Net loss per share attributable to common stockholders:
Net loss	$ (18,292)	$ (10,716)
Cumulative dividend on convertible preferred stock	(1,343)	(1,345)
Net loss attributable to common stockholders	$ (19,635)	$ (12,061)
Weighted average number of common shares and equivalents:	76,061,183	75,558,233
Basic EPS	$ (0.26)	$ (0.16)
Diluted EPS	$ (0.26)	$ (0.16)

Schedule of Anti-Dilutive Secur

Schedule of Anti-Dilutive Securities Excluded From Computation of Diluted Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	57,391,141	54,899,045
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	3,208,065	2,818,012
Series A Convertible Preferred Stock and Accumulated Dividends [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	47,364,216	45,306,189
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	5,610,121	5,610,121
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common shares excluded from the computation of diluted earnings per share	1,208,739	1,164,723

Employee Benefit Plan (Details

Employee Benefit Plan (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, cost	$ 0.3	$ 0.3
Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Percentage of employee contributions participating employee's compensation	3%

Schedule of Accrued Warranty (D

Schedule of Accrued Warranty (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Guarantees and Product Warranties [Abstract]
Warranty accrual, beginning of the fiscal period	$ 242	$ 158
Accrual adjustment for product warranty	113	199
Payments made	(192)	(115)
Warranty accrual, end of the fiscal period	$ 163	$ 242

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) $ in Millions	Apr. 30, 2021 USD ($)
Letter of Credit [Member]
Line of Credit Facility [Line Items]
Long-term line of credit	$ 1.8

Schedule of Geographic Revenues

Schedule of Geographic Revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Total	$ 28,147	$ 35,021
Operating Segments [Member] | UNITED STATES
Segment Reporting Information [Line Items]
Total	19,708	20,360
Operating Segments [Member] | Non-US [Member]
Segment Reporting Information [Line Items]
Total	$ 8,439	$ 14,661